$TPB

Turning Point Brands, Inc. (TPB): Results of Operations and Financial Condition

Turning Point Brands, Inc. (TPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turning Point Brands Announces Second Quarter 2026 Results ● Q2 2026 Modern Oral Gross Revenue increased 149% to $87.0 million and Net Sales increased 128% to $68.4 million. Accounting for 48% of total company net sales, up from 26% in Q2 2025 ● Raising FY 2026 Moder

Original reporting
Published Aug 4, 2026, 12:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$TPB
Bullish
medium confidence
Mentioned
$TPB
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TPBBullishHigh
01

Why it matters

The most actionable update is the raised FY 2026 Modern Oral gross and net sales guidance, supported by triple-digit Modern Oral growth in Q2. However, profitability metrics (GAAP net income and adjusted EBITDA) declined sharply YoY, and SG&A rose materially, increasing execution risk.

02

Market read

Traders can update TPB positioning ahead of the scheduled earnings call based on the raised Modern Oral outlook and the disclosed profitability/mix tradeoffs.

03

What to watch

Gross profit growth is partly driven by a tariff refund and out-of-period COGS adjustments; traders should normalize margins and watch whether the Modern Oral mix sustains gross profit percentage (down to 56.9% from 62.5%).

Relevance 7/10Novelty 9/10Timing: pre-market today, filed Aug 4, 2026 with earnings call scheduled 9:00 a.m. ET

Background

SEC 8-K Item 2.02 with Exhibit 99.1 press release covering Turning Point Brands Q2 2026 financial results and FY 2026 outlook.

Company-level read

Ticker impact

$TPBBullishMedium confidence
Context

Turning Point Brands reports Q2 2026 results and raises FY 2026 Modern Oral gross and net sales guidance, with Modern Oral now 48% of net sales.

Expected impact

Likely near-term positive bias as traders reprice FY Modern Oral growth and margin trajectory, while monitoring the SG&A and adjusted EBITDA decline.

Evidence & confidence

The filing includes explicit Q2 datapoints (Modern Oral gross revenue +149%, net sales +128%) and a quantified FY 2026 outlook update (Modern Oral gross $330-$350m, net $260-$270m; Adjusted EBITDA $70-$90m). The negative GAAP/adjusted profitability trend adds uncertainty but does not negate the guidance upgrade.

Market effects

Signals demand shift toward modern oral nicotine products and potential margin/mix dynamics for alternative smoking accessory manufacturers.

Primarily US-focused retail distribution footprint (220,000 outlets in North America) may influence sentiment toward domestic consumer nicotine categories.

Limited direct global read-through; guidance is company-specific and tied to its product mix and tariff-related accounting.

Counterpoint

The guidance raise may be offset by structurally higher SG&A and freight costs, and adjusted EBITDA fell 50% YoY despite revenue growth.

Key entities

  • Turning Point Brands, Inc.

    Manufacturer and marketer/distributor of branded consumer products including alternative smoking accessories and consumables; subject of the 8-K.

  • Modern Oral

    Product category highlighted as the growth driver, with Q2 gross revenue +149% and FY 2026 guidance raised.

  • Stoker’s Products Segment

    Largest segment (75% of net sales in the quarter) with Q2 net sales +54.5% driven by Modern Oral.

  • Zig-Zag Products Segment

    Smaller segment (25% of net sales in the quarter) with Q2 net sales down 24.8% YoY.

Related articles

$HDBMed

Banks accelerate capital increases with billions of new shares

Vietnamese banks are accelerating charter-capital increases via bonus shares, stock dividends and rights issues. BIDV plans a 498.2m-share bonus issuance (record Aug 18) and a 4.5% cash dividend (Aug 20). Vietcombank and VietinBank also plan 4.5% cash dividends in late August. Other lenders including MBBank, HDBank, TPBank, VIB, Maritime Bank, VietABank and Vietbank outline additional share issuances and a Vietbank rights offer.

$TPBMedAI 8/10

Turning Point Brands Q2 Earnings Call Highlights

Turning Point Brands (NYSE:TPB) reported Q2 segment updates and raised 2026 Modern Oral outlook. Adjusted gross sales guidance for Modern Oral increased to $330M-$350M and net sales to $260M-$270M. It kept full-year adjusted EBITDA at $70M-$90M. The company said it ended Q2 with $268M cash and $26M free cash flow, helped by an $18M tariff refund.

$TPBMedAI 9/10

Turning Point Brands Inc. (TPB): A Top Sin Stock to Buy On Growing Nicotine Pouch Opportunity

Turning Point Brands (NYSE:TPB) reported first-quarter results on May 7. Revenue rose 17% year over year to $124.3 million, driven by growth in its Modern Oral nicotine pouch segment. Gross profit increased 14.6% to $68.3 million, while adjusted EBITDA fell 6.5% to $25.9 million as margins contracted to 20.8%. The company said it is investing in sales, marketing, and manufacturing and targets double-digit market share by 2030.

$IPHAMed

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma (IPHA) reported Q2 2026 earnings, highlighting a cash position of -€21.4M, a $75M upfront payment from Sobi, and -€28M in net equity proceeds. H1 2026 net loss was -€19.6M, with revenue of -€5.7M. The company extended its cash runway to Q1 2028 and anticipates key milestones, including a Phase 3 readout for monalizumab and initial data for IPH4502. Management expects to file for accelerated approval of lacutamab in Sezary Syndrome in H2 2027.

$UPXIMed

Upexi Inc (UPXI) (Q4 2026) Earnings Call Highlights: Massive Solana Treasury Fuels $246

Upexi Inc. (UPXI) reported Q4 2026 earnings, highlighting a $246M net loss driven by digital asset losses. CEO Alan Marshall discussed Solana treasury management, debt restructuring, and cost-cutting efforts. The company holds 2.34M Solana tokens, with staking revenue covering expenses. Management emphasized creative capital allocation and potential expansion in Asian markets through the Hivemind partnership. Stockholders' equity was negative $53.8M as of June 30, 2026.

$RBAMedAI 8/10

RB Global’s (RBA) Earnings Jump While Its Take Rate Shrinks

RB Global (RBA) reported Q2 earnings with net income up 33% YoY to $132M, EPS up 34% to $0.71, and revenue up 11% to $1.3B. Automotive segment drove GTV growth of 13%. Acquisitions boosted growth, but organic GTV growth was 7%. Service revenue take rate fell 110 bps to 20.0%. Management raised full-year guidance and increased the dividend. Hedge fund ownership declined, and short interest is high at 10.54% of float.